14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.91 $2.54 Thursday, 2nd May 2024 CANF stock ended at $2.03. This is 2.87% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 9.44% from a day low at $2.01 to a day high of $2.20.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Nov 04, 2021 $1.51 $1.56 $1.48 $1.52 186 951
Nov 03, 2021 $1.50 $1.54 $1.48 $1.49 164 237
Nov 02, 2021 $1.48 $1.57 $1.47 $1.51 521 582
Nov 01, 2021 $1.55 $1.55 $1.47 $1.51 248 515
Oct 29, 2021 $1.52 $1.55 $1.50 $1.52 87 634
Oct 28, 2021 $1.59 $1.60 $1.49 $1.50 258 679
Oct 27, 2021 $1.50 $1.63 $1.49 $1.55 613 946
Oct 26, 2021 $1.51 $1.55 $1.48 $1.50 299 208
Oct 25, 2021 $1.53 $1.55 $1.50 $1.55 85 058
Oct 22, 2021 $1.54 $1.56 $1.51 $1.53 145 683
Oct 21, 2021 $1.64 $1.66 $1.54 $1.57 270 870
Oct 20, 2021 $1.57 $1.59 $1.55 $1.56 66 168
Oct 19, 2021 $1.57 $1.59 $1.55 $1.56 118 052
Oct 18, 2021 $1.55 $1.57 $1.54 $1.55 67 193
Oct 15, 2021 $1.55 $1.57 $1.52 $1.55 91 096
Oct 14, 2021 $1.55 $1.65 $1.55 $1.58 126 885
Oct 13, 2021 $1.54 $1.57 $1.53 $1.55 120 843
Oct 12, 2021 $1.56 $1.61 $1.53 $1.56 157 397
Oct 11, 2021 $1.50 $1.57 $1.50 $1.54 336 022
Oct 08, 2021 $1.55 $1.56 $1.49 $1.49 301 388
Oct 07, 2021 $1.53 $1.56 $1.49 $1.53 142 304
Oct 06, 2021 $1.56 $1.60 $1.48 $1.51 195 107
Oct 05, 2021 $1.62 $1.63 $1.57 $1.57 215 824
Oct 04, 2021 $1.63 $1.64 $1.57 $1.62 137 992
Oct 01, 2021 $1.67 $1.68 $1.61 $1.64 103 527
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT